{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:24:38Z","timestamp":1792657478347,"version":"4.5.0"},"reference-count":297,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"\n Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a\n BCR::ABL1<\/jats:italic>\n fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase\u2013CML. The primary goal of TKI therapy in patients with chronic phase\u2013CML is to prevent disease progression to accelerated phase\u2013CML or blast phase\u2013CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase\u2013CML.\n <\/jats:p>","DOI":"10.6004\/jnccn.2024.0007","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:30:09Z","timestamp":1708702209000},"page":"43-69","source":"Crossref","is-referenced-by-count":137,"title":["Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"22","author":[{"given":"Neil P.","family":"Shah","sequence":"first","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amaya","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellin","family":"Berman","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Clements","sequence":"additional","affiliation":[{"name":"CML Buster Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Collins","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Curtin","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Drazer","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Maness","sequence":"additional","affiliation":[{"name":"Fred and Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland","family":"Metheny","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mohan","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Moore","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Oehler","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pratz","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal G.","family":"Rose","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shomali","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Styler","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany N.","family":"Tanaka","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Tantravahi","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thompson","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tsai","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Vaughn","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"Welborn","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yang","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gregory","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Cancer statistics, 2023. CA Cancer J Clin 2023;73:17\u201348."},{"key":"B2","series-title":"N Engl J Med","first-page":"164","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl S","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164\u2013172."},{"key":"B3","series-title":"Blood","first-page":"2375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo JV","year":"1996","unstructured":"Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375\u20132384."},{"key":"B4","series-title":"Baillieres Clin Haematol","first-page":"203","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo JV","year":"1997","unstructured":"Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997;10:203\u2013222."},{"key":"B5","series-title":"N Engl J Med","first-page":"1330","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers CL","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330\u20131340."},{"key":"B6","series-title":"Proc Natl Acad Sci USA","first-page":"2794","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich JP","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794\u20132799."},{"key":"B7","series-title":"N Engl J Med","first-page":"657","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson CH","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657\u2013667."},{"key":"B8","series-title":"Blood","first-page":"3794","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes JE","year":"2003","unstructured":"Cortes JE, Talpaz M, Giles F, Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794\u20133800."},{"key":"B9","series-title":"Blood","first-page":"451","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O\u2019Dwyer ME","year":"2004","unstructured":"O\u2019Dwyer ME, Mauro MJ, Blasdel C, Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451\u2013455."},{"key":"B10","series-title":"Blood","first-page":"1699","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang W","year":"2015","unstructured":"Wang W, Cortes JE, Lin P, Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 2015;126:1699\u20131706."},{"key":"B11","series-title":"J Hematol Oncol","first-page":"32","article-title":"Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis","volume":"8","author":"Wang W","year":"2015","unstructured":"Wang W, Tang G, Cortes JE, Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol 2015;8:32."},{"key":"B12","series-title":"Blood","first-page":"2742","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang W","year":"2016","unstructured":"Wang W, Cortes JE, Tang G, Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016;127:2742\u20132750."},{"key":"B13","series-title":"Anticancer Res","first-page":"2535","article-title":"Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment","volume":"24","author":"Douet-Guilbert N","year":"2004","unstructured":"Douet-Guilbert N, Morel F, Le Charpentier T, Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res 2004;24:2535\u20132539."},{"key":"B14","series-title":"Blood","first-page":"2343","article-title":"Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment","volume":"86","author":"Seong DC","year":"1995","unstructured":"Seong DC, Kantarjian HM, Ro JY, Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995;86:2343\u20132349."},{"key":"B15","series-title":"Blood","first-page":"3357","article-title":"Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy in chronic myeloid leukemia","volume":"91","author":"Dewald GW","year":"1998","unstructured":"Dewald GW, Wyatt WA, Juneau AL, Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357\u20133365."},{"key":"B16","series-title":"Clin Cancer Res","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian HM","year":"2003","unstructured":"Kantarjian HM, Talpaz M, Cortes J, Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160\u2013166."},{"key":"B17","series-title":"Blood","first-page":"28","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes T","year":"2006","unstructured":"Hughes T, Deininger MW, Hochhaus A, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28\u201337."},{"key":"B18","series-title":"Blood","first-page":"3118","article-title":"Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux C","year":"1995","unstructured":"Biernaux C, Loos M, Sels A, Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118\u20133122."},{"key":"B19","series-title":"Blood","first-page":"3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose S","year":"1998","unstructured":"Bose S, Deininger MW, Gora-Tybor J, The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362\u20133367."},{"key":"B20","series-title":"Leukemia","first-page":"1173","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani M","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 2019;33:1173\u20131183."},{"key":"B21","series-title":"Leuk Res","first-page":"106512","article-title":"The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"101","author":"Ghalesardi OK","year":"2021","unstructured":"Ghalesardi OK, Khosravi A, Azizi E, The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: a systematic review and meta-analysis. Leuk Res 2021;101:106512."},{"key":"B22","series-title":"Haematologica","first-page":"1362","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas CM","year":"2009","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 2009;94:1362\u20131367."},{"key":"B23","series-title":"Haematologica","first-page":"1441","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein B","year":"2014","unstructured":"Hanfstein B, Lauseker M, Hehlmann R, Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 2014;99:1441\u20131447."},{"key":"B24","series-title":"Blood","first-page":"1269","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain P","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP, Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 2016;127:1269\u20131275."},{"key":"B25","series-title":"Am J Hematol","first-page":"797","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti F","year":"2017","unstructured":"Castagnetti F, Gugliotta G, Breccia M, The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol 2017;92:797\u2013805."},{"key":"B26","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"728","article-title":"Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"17","author":"Pagnano KB","year":"2017","unstructured":"Pagnano KB, Miranda EC, Delamain MT, Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. Clin Lymphoma Myeloma Leuk 2017;17:728\u2013733."},{"key":"B27","series-title":"Leuk Lymphoma","first-page":"105","article-title":"Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy","volume":"59","author":"Lee SE","year":"2018","unstructured":"Lee SE, Choi SY, Kim SH, Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy. Leuk Lymphoma 2018;59:105\u2013113."},{"key":"B28","series-title":"Cancer","first-page":"3806","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan A","year":"2018","unstructured":"Ercaliskan A, Eskazan AE. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer 2018;124:3806\u20133818."},{"key":"B29","series-title":"J Cancer Res Clin Oncol","first-page":"843","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann M","year":"2017","unstructured":"Pfirrmann M, Evtimova D, Saussele S, No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol 2017;143:843\u2013850."},{"key":"B30","series-title":"Oncotarget","first-page":"2560","article-title":"Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib","volume":"11","author":"Genthon A","year":"2020","unstructured":"Genthon A, Nicolini FE, Huguet F, Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. Oncotarget 2020;11:2560\u20132570."},{"key":"B31","series-title":"Leukemia","first-page":"1879","article-title":"Impact of BCR:ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy","volume":"36","author":"Salmon M","year":"2022","unstructured":"Salmon M, White HE, Zizkova H, Impact of BCR:ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia 2022;36:1879\u20131886."},{"key":"B32","series-title":"Blood","first-page":"2232","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma D","year":"2009","unstructured":"Verma D, Kantarjian HM, Jones D, Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 2009;114:2232\u20132235."},{"key":"B33","series-title":"Int J Lab Hematol","first-page":"235","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients","volume":"39","author":"Arun AK","year":"2017","unstructured":"Arun AK, Senthamizhselvi A, Mani S, Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol 2017;39:235\u2013242."},{"key":"B34","series-title":"Blood Cancer J","first-page":"e583","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong Z","year":"2017","unstructured":"Gong Z, Medeiros LJ, Cortes JE, Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J 2017;7:e583."},{"key":"B35","series-title":"Br J Haematol","first-page":"693","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre","volume":"182","author":"Qin YZ","year":"2018","unstructured":"Qin YZ, Jiang Q, Jiang H, Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol 2018;182:693\u2013700."},{"key":"B36","series-title":"Leuk Lymphoma","first-page":"3051","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue M","year":"2019","unstructured":"Xue M, Wang Q, Huo L, Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts. Leuk Lymphoma 2019;60:3051\u20133057."},{"key":"B37","series-title":"Leukemia","first-page":"1964","article-title":"Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets","volume":"35","author":"Adnan-Awad S","year":"2021","unstructured":"Adnan-Awad S, Kim D, Hohtari H, Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia 2021;35:1964\u20131975."},{"key":"B38","series-title":"Blood Cancer J","first-page":"103","article-title":"Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases","volume":"12","author":"Abdelmagid MG","year":"2022","unstructured":"Abdelmagid MG, Litzow MR, McCullough KB, Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases. Blood Cancer J 2022;12:103."},{"key":"B39","series-title":"Cancer","first-page":"2416","article-title":"Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR\/ABL mRNA and undetectable BCR\/ABL protein may predict an indolent course","volume":"94","author":"Verstovsek S","year":"2002","unstructured":"Verstovsek S, Lin H, Kantarjian H, Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR\/ABL mRNA and undetectable BCR\/ABL protein may predict an indolent course. Cancer 2002;94:2416\u20132425."},{"key":"B40","series-title":"Case Rep Hematol","first-page":"458716","article-title":"Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring","volume":"2012","author":"Langabeer SE","year":"2012","unstructured":"Langabeer SE, McCarron SL, Kelly J, Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring. Case Rep Hematol 2012;2012:458716."},{"key":"B41","series-title":"Hematol Oncol Stem Cell Ther","first-page":"85","article-title":"Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: implications for molecular monitoring","volume":"10","author":"Crampe M","year":"2017","unstructured":"Crampe M, Haslam K, Kelly J, Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: implications for molecular monitoring. Hematol Oncol Stem Cell Ther 2017;10:85\u201388."},{"key":"B42","series-title":"Arch Pathol Lab Med","first-page":"969","article-title":"Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"139","author":"Langabeer SE","year":"2015","unstructured":"Langabeer SE. Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia. Arch Pathol Lab Med 2015;139:969."},{"key":"B43","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"168","article-title":"Molecular monitoring in CML: how deep? How often? How should it influence therapy?","volume":"2018","author":"Shanmuganathan N","year":"2018","unstructured":"Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematology Am Soc Hematol Educ Program 2018;2018:168\u2013176."},{"key":"B44","series-title":"Leuk Res","first-page":"579","article-title":"A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister T","year":"2008","unstructured":"Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 2008;32:579\u2013585."},{"key":"B45","series-title":"Clin Lab","first-page":"433","article-title":"Comprehensive analysis of BCR\/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR","volume":"58","author":"Bennour A","year":"2012","unstructured":"Bennour A, Ouahchi I, Moez M, Comprehensive analysis of BCR\/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR. Clin Lab 2012;58:433\u2013439."},{"key":"B46","series-title":"Indian J Cancer","first-page":"314","article-title":"Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients","volume":"52","author":"Mir R","year":"2015","unstructured":"Mir R, Ahmad I, Javid J, Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer 2015;52:314\u2013318."},{"key":"B47","series-title":"Leuk Lymphoma","first-page":"2527","article-title":"Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"61","author":"Pagani IS","year":"2020","unstructured":"Pagani IS, Dang P, Saunders VA, Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leuk Lymphoma 2020;61:2527\u20132529."},{"key":"B48","series-title":"J Clin Med","first-page":"1457","article-title":"Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts","volume":"9","author":"Petiti J","year":"2020","unstructured":"Petiti J, Lo Iacono M, Dragani M, Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts. J Clin Med 2020;9:1457."},{"key":"B49","series-title":"Cancer","first-page":"2673","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma D","year":"2010","unstructured":"Verma D, Kantarjian H, Shan J, Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673\u20132681."},{"key":"B50","series-title":"Ann Hematol","first-page":"2015","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius A","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015;94:2015\u20132024."},{"key":"B51","series-title":"Blood","first-page":"6760","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius A","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118:6760\u20136768."},{"key":"B52","series-title":"Leukemia","first-page":"2074","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann R","year":"2020","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;34:2074\u20132086."},{"key":"B53","series-title":"Am J Hematol","first-page":"84","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji A","year":"2018","unstructured":"Alhuraiji A, Kantarjian H, Boddu P, Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 2018;93:84\u201390."},{"key":"B54","series-title":"Blood","first-page":"1941","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm T","year":"2003","unstructured":"Bumm T, M\u00fcller C, Al-Ali HK, Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941\u20131949."},{"key":"B55","series-title":"Exp Hematol","first-page":"702","article-title":"The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"31","author":"Feldman E","year":"2003","unstructured":"Feldman E, Najfeld V, Schuster M, The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702\u2013707."},{"key":"B56","series-title":"Cancer","first-page":"1905","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina J","year":"2003","unstructured":"Medina J, Kantarjian H, Talpaz M, Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905\u20131911."},{"key":"B57","series-title":"Leukemia","first-page":"1340","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre C","year":"2004","unstructured":"Terre C, Eclache V, Rousselot P, Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18:1340\u20131346."},{"key":"B58","series-title":"Cancer","first-page":"1509","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger MW","year":"2007","unstructured":"Deininger MW, Cortes J, Paquette R, The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110:1509\u20131519."},{"key":"B59","series-title":"Blood","first-page":"2991","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour E","year":"2007","unstructured":"Jabbour E, Kantarjian HM, Abruzzo LV, Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991\u20132995."},{"key":"B60","series-title":"Blood","first-page":"3676","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol","volume":"109","author":"Vignetti M","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676\u20133678."},{"key":"B61","series-title":"Haematologica","first-page":"834","article-title":"Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure","volume":"92","author":"Fabarius A","year":"2007","unstructured":"Fabarius A, Haferlach C, M\u00fcller MC, Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007;92:834\u2013837."},{"key":"B62","series-title":"Leuk Res","first-page":"e218","article-title":"Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy","volume":"33","author":"Baldazzi C","year":"2009","unstructured":"Baldazzi C, Luatti S, Marzocchi G, Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res 2009;33:e218\u2013220."},{"key":"B63","series-title":"Ann Hematol","first-page":"1625","article-title":"Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy","volume":"92","author":"Wang H","year":"2013","unstructured":"Wang H, Jin J, Wang Y, Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy. Ann Hematol 2013;92:1625\u20131632."},{"key":"B64","series-title":"Cancer Genet","first-page":"44","article-title":"Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors","volume":"238","author":"Ni H","year":"2019","unstructured":"Ni H, Sun X, Xu Y, Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors. Cancer Genet 2019;238:44\u201349."},{"key":"B65","series-title":"Leuk Lymphoma","first-page":"3503","article-title":"Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments","volume":"60","author":"Sheng G","year":"2019","unstructured":"Sheng G, Xue M, Wang Q, Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments. Leuk Lymphoma 2019;60:3503\u20133511."},{"key":"B66","series-title":"Blood","first-page":"2084","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa GC","year":"2017","unstructured":"Issa GC, Kantarjian HM, Gonzalez GN, Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 2017;130:2084\u20132091."},{"key":"B67","series-title":"Intern Med","first-page":"481","article-title":"Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia","volume":"50","author":"Karimata K","year":"2011","unstructured":"Karimata K, Masuko M, Ushiki T, Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Intern Med 2011;50:481\u2013485."},{"key":"B68","series-title":"Am J Hematol","first-page":"849","article-title":"Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome","volume":"82","author":"Navarro JT","year":"2007","unstructured":"Navarro JT, Feliu E, Grau J, Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol 2007;82:849\u2013851."},{"key":"B69","series-title":"Haematologica","first-page":"1150","article-title":"Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet A","year":"2019","unstructured":"Bidet A, Dulucq S, Smol T, Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica 2019;104:1150\u20131155."},{"key":"B70","series-title":"Blood","first-page":"789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal JE","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 1984;63:789\u2013799."},{"key":"B71","series-title":"J Natl Cancer Inst","first-page":"850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford J","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850\u2013858."},{"key":"B72","series-title":"Leukemia","first-page":"48","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann M","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016;30:48\u201356."},{"key":"B73","series-title":"Leukemia","first-page":"557","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann V","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M, A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011;25:557\u2013560."},{"key":"B74","series-title":"Blood","first-page":"e198","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima H","year":"2011","unstructured":"Makishima H, Jankowska AM, McDevitt MA, CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011;117:e198\u2013206."},{"key":"B75","series-title":"Leuk Res","first-page":"142","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim T","year":"2017","unstructured":"Kim T, Tyndel MS, Zhang Z, Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk Res 2017;59:142\u2013148."},{"key":"B76","series-title":"Blood","first-page":"38","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim T","year":"2017","unstructured":"Kim T, Tyndel MS, Kim HJ, Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 2017;129:38\u201347."},{"key":"B77","series-title":"Am J Hematol","first-page":"E623","article-title":"Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients","volume":"92","author":"Mologni L","year":"2017","unstructured":"Mologni L, Piazza R, Khandelwal P, Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. Am J Hematol 2017;92:E623\u2013625."},{"key":"B78","series-title":"Blood Cancer J","first-page":"e559","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki E","year":"2017","unstructured":"Togasaki E, Takeda J, Yoshida K, Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia. Blood Cancer J 2017;7:e559."},{"key":"B79","series-title":"Blood","first-page":"948","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford S","year":"2018","unstructured":"Branford S, Wang P, Yeung DT, Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 2018;132:948\u2013961."},{"key":"B80","series-title":"Leuk Lymphoma","first-page":"200","article-title":"Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors","volume":"60","author":"Erbilgin Y","year":"2019","unstructured":"Erbilgin Y, Eskazan AE, Hatirnaz Ng \u00d6, Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leuk Lymphoma 2019;60:200\u2013207."},{"key":"B81","series-title":"Haematologica","first-page":"2400","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos G","year":"2019","unstructured":"Nteliopoulos G, Bazeos A, Claudiani S, Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica 2019;104:2400\u20132409."},{"key":"B82","series-title":"Blood Adv","first-page":"546","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad S","year":"2020","unstructured":"Adnan Awad S, Kankainen M, Ojala T, Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv 2020;4:546\u2013559."},{"key":"B83","series-title":"Onco Targets Ther","first-page":"8581","article-title":"Integrative genomic analysis reveals cancer-associated gene mutations in chronic myeloid leukemia patients with resistance or intolerance to tyrosine kinase inhibitor","volume":"13","author":"Wu W","year":"2020","unstructured":"Wu W, Xu N, Zhou X, Integrative genomic analysis reveals cancer-associated gene mutations in chronic myeloid leukemia patients with resistance or intolerance to tyrosine kinase inhibitor. Onco Targets Ther 2020;13:8581\u20138591."},{"key":"B84","series-title":"Leukemia","first-page":"1087","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Adnan Awad S","year":"2021","unstructured":"Adnan Awad S, Dufva O, Ianevski A, RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia 2021;35:1087\u20131099."},{"key":"B85","series-title":"Nat Commun","first-page":"2833","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi Y","year":"2021","unstructured":"Ochi Y, Yoshida K, Huang YJ, Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun 2021;12:2833."},{"key":"B86","series-title":"Blood Cancer J","first-page":"144","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian A","year":"2022","unstructured":"Bidikian A, Kantarjian H, Jabbour E, Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J 2022;12:144."},{"key":"B87","series-title":"Leukemia","first-page":"2242","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld L","year":"2022","unstructured":"Sch\u00f6nfeld L, Rinke J, Hinze A, ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia 2022;36:2242\u20132249."},{"key":"B88","series-title":"Blood Cancer J","first-page":"69","article-title":"Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation","volume":"12","author":"Adnan Awad S","year":"2022","unstructured":"Adnan Awad S, Br\u00fcck O, Shanmuganathan N, Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer J 2022;12:69."},{"key":"B89","series-title":"Lancet Haematol","first-page":"e276","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors A","year":"2019","unstructured":"Kizilors A, Cris\u00e0 E, Lea N, Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Lancet Haematol 2019;6:e276\u2013284."},{"key":"B90","series-title":"Blood","first-page":"534","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini S","year":"2020","unstructured":"Soverini S, Bavaro L, De Benedittis C, Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood 2020;135:534\u2013541."},{"key":"B91","series-title":"Leukemia","first-page":"2292","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt M","year":"2014","unstructured":"Schmidt M, Rinke J, Sch\u00e4fer V, Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 2014;28:2292\u20132299."},{"key":"B92","series-title":"N Engl J Med","first-page":"917","article-title":"Long-term outcomes of imatinib treatment of chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Long-term outcomes of imatinib treatment of chronic myeloid leukemia. N Engl J Med 2017;376:917\u2013927."},{"key":"B93","series-title":"J Clin Oncol","first-page":"2333","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333\u20132340."},{"key":"B94","series-title":"J Clin Oncol","first-page":"231","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018;36:231\u2013237."},{"key":"B95","series-title":"Leukemia","first-page":"1825","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf TH","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia 2022;36:1825\u20131833."},{"key":"B96","series-title":"Leukemia","first-page":"440","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35:440\u2013453."},{"key":"B97","series-title":"Blood Res","first-page":"139","article-title":"Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study","volume":"55","author":"Gemelli M","year":"2020","unstructured":"Gemelli M, Elli EM, Elena C, Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. Blood Res 2020;55:139\u2013145."},{"key":"B98","series-title":"Ann Hematol","first-page":"2773","article-title":"Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients","volume":"99","author":"Scalzulli E","year":"2020","unstructured":"Scalzulli E, Colafigli G, Latagliata R, Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. Ann Hematol 2020;99:2773\u20132777."},{"key":"B99","series-title":"Blood Adv","first-page":"3344","article-title":"Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs","volume":"5","author":"Er\u00e7al\u0131\u015fkan A","year":"2021","unstructured":"Er\u00e7al\u0131\u015fkan A, Seyhan Erdo\u011fan D, E\u015fkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv 2021;5:3344\u20133353."},{"key":"B100","series-title":"Lancet Haematol","first-page":"e854","article-title":"The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA","volume":"9","author":"Kantarjian HM","year":"2022","unstructured":"Kantarjian HM, Paul S, Thakkar J, The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol 2022;9:e854\u2013861."},{"key":"B101","series-title":"Int J Hematol","first-page":"616","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani M","year":"2014","unstructured":"Baccarani M, Druker BJ, Branford S, Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014;99:616\u2013624."},{"key":"B102","series-title":"Br J Haematol","first-page":"223","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger MW","year":"2014","unstructured":"Deininger MW, Kopecky KJ, Radich JP, Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014;164:223\u2013232."},{"key":"B103","series-title":"Leukemia","first-page":"2398","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann R","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017;31:2398\u20132406."},{"key":"B104","series-title":"J Cancer Res Clin Oncol","first-page":"1311","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann VS","year":"2017","unstructured":"Hoffmann VS, Hasford J, Deininger MW, Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. J Cancer Res Clin Oncol 2017;143:1311\u20131318."},{"key":"B105","series-title":"Blood","first-page":"261","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quint\u00e1s-Cardama A","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Han X, Kantarjian HM, Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261\u2013263."},{"key":"B106","series-title":"Haematologica","first-page":"93","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Laneuville P, Rousselot P, Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 2019;104:93\u2013101."},{"key":"B107","series-title":"Cancer","first-page":"377","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka K","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377\u2013386."},{"key":"B108","series-title":"Circulation","first-page":"2128","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani D","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128\u20132137."},{"key":"B109","series-title":"Leuk Res","first-page":"e4","article-title":"Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia","volume":"36","author":"Orlandi EM","year":"2012","unstructured":"Orlandi EM, Rocca B, Pazzano AS, Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e4\u20136."},{"key":"B110","series-title":"Cancers (Basel)","first-page":"826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS)","volume":"12","author":"Cirmi S","year":"2020","unstructured":"Cirmi S, El Abd A, Letinier L, Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel) 2020;12:826."},{"key":"B111","series-title":"Leukemia","first-page":"1511","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace F","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27:1511\u20131519."},{"key":"B112","series-title":"N Engl J Med","first-page":"2006","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman E","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG, Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006\u20132013."},{"key":"B113","series-title":"Leuk Res","first-page":"790","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman E","year":"2013","unstructured":"Berman E, Girotra M, Cheng C, Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 2013;37:790\u2013794."},{"key":"B114","series-title":"Cancer","first-page":"2483","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao AS","year":"2003","unstructured":"Tsao AS, Kantarjian HM, Cortes JE, Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483\u20132487."},{"key":"B115","series-title":"Hematol Oncol Stem Cell Ther","first-page":"358","article-title":"Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia","volume":"2","author":"Aleem A","year":"2009","unstructured":"Aleem A. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 2009;2:358\u2013361."},{"key":"B116","series-title":"Int J Hematol","first-page":"292","article-title":"Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia","volume":"109","author":"Sakurai M","year":"2019","unstructured":"Sakurai M, Kikuchi T, Karigane D, Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol 2019;109:292\u2013298."},{"key":"B117","series-title":"Leukemia","first-page":"1925","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold U","year":"2003","unstructured":"Reinhold U, Hennig E, Leiblein S, FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia 2003;17:1925\u20131929."},{"key":"B118","series-title":"J Exp Clin Cancer Res","first-page":"295","article-title":"Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with imatinib mesylate","volume":"23","author":"Fugazza G","year":"2004","unstructured":"Fugazza G, Miglino M, Bruzzone R, Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with imatinib mesylate. J Exp Clin Cancer Res 2004;23:295\u2013299."},{"key":"B119","series-title":"Leuk Lymphoma","first-page":"2055","article-title":"Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR\/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia","volume":"47","author":"Landstrom AP","year":"2006","unstructured":"Landstrom AP, Ketterling RP, Knudson RA, Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR\/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma 2006;47:2055\u20132061."},{"key":"B120","series-title":"Blood","first-page":"4939","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni N","year":"2009","unstructured":"Testoni N, Marzocchi G, Luatti S, Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009;114:4939\u20134943."},{"key":"B121","series-title":"Cancer","first-page":"1245","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima L","year":"2011","unstructured":"Lima L, Bernal-Mizrachi L, Saxe D, Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011;117:1245\u20131252."},{"key":"B122","series-title":"Blood","first-page":"3758","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes TP","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758\u20133765."},{"key":"B123","series-title":"Arch Pathol Lab Med","first-page":"1186","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study","volume":"138","author":"Akard LP","year":"2014","unstructured":"Akard LP, Cortes JE, Albitar M, Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Arch Pathol Lab Med 2014;138:1186\u20131192."},{"key":"B124","series-title":"Leukemia","first-page":"1925","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford S","year":"2006","unstructured":"Branford S, Cross NC, Hochhaus A, Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925\u20131930."},{"key":"B125","series-title":"Best Pract Res Clin Haematol","first-page":"355","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross NC","year":"2009","unstructured":"Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355\u2013365."},{"key":"B126","series-title":"Leukemia","first-page":"2172","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross NC","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172\u20132175."},{"key":"B127","series-title":"Blood","first-page":"3330","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford S","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330\u20133338."},{"key":"B128","series-title":"Curr Med Res Opin","first-page":"1345","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Gu\u00e9rin A","year":"2014","unstructured":"Gu\u00e9rin A, Chen L, Dea K, Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin 2014;30:1345\u20131352."},{"key":"B129","series-title":"Leukemia","first-page":"2096","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein B","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096\u20132102."},{"key":"B130","series-title":"J Clin Oncol","first-page":"232","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin D","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232\u2013238."},{"key":"B131","series-title":"Blood","first-page":"2739","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan P","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013;121:2739\u20132742."},{"key":"B132","series-title":"Haematologica","first-page":"1686","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha A","year":"2013","unstructured":"Nazha A, Kantarjian HM, Jain P, Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 2013;98:1686\u20131688."},{"key":"B133","series-title":"Blood","first-page":"511","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford S","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014;124:511\u2013518."},{"key":"B134","series-title":"Leukemia","first-page":"1988","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein B","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014;28:1988\u20131992."},{"key":"B135","series-title":"Am J Hematol","first-page":"282","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama N","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol 2015;90:282\u2013287."},{"key":"B136","series-title":"Leukemia","first-page":"1054","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus A","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054\u20131061."},{"key":"B137","series-title":"Blood","first-page":"4541","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour E","year":"2011","unstructured":"Jabbour E, Kantarjian HM, O\u2019Brien S, The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011;118:4541\u20134546; quiz 4759."},{"key":"B138","series-title":"N Engl J Med","first-page":"2408","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker BJ","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408\u20132417."},{"key":"B139","series-title":"Clin Cancer Res","first-page":"6136","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press RD","year":"2007","unstructured":"Press RD, Galderisi C, Yang R, A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136\u20136143."},{"key":"B140","series-title":"J Clin Oncol","first-page":"3358","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade H","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358\u20133363."},{"key":"B141","series-title":"Blood","first-page":"4437","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin D","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437\u20134444."},{"key":"B142","series-title":"J Clin Oncol","first-page":"4260","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour E","year":"2011","unstructured":"Jabbour E, Kantarjian HM, O\u2019Brien S, Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011;29:4260\u20134265."},{"key":"B143","series-title":"J Clin Oncol","first-page":"415","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann R","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014;32:415\u2013423."},{"key":"B144","series-title":"Leukemia","first-page":"1222","article-title":"Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV","volume":"32","author":"Saussele S","year":"2018","unstructured":"Saussele S, Hehlmann R, Fabarius A, Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia 2018;32:1222\u20131228."},{"key":"B145","series-title":"Haematologica","first-page":"1317","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes F","year":"2010","unstructured":"Cervantes F, L\u00f3pez-Garrido P, Montero MI, Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010;95:1317\u20131324."},{"key":"B146","series-title":"J Clin Oncol","first-page":"1512","article-title":"Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy","volume":"29","author":"Kantarjian HM","year":"2011","unstructured":"Kantarjian HM, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:1512\u20131516."},{"key":"B147","series-title":"Leukemia","first-page":"966","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966\u2013984."},{"key":"B148","series-title":"Blood","first-page":"473","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian HM","year":"2003","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473\u2013475."},{"key":"B149","series-title":"Blood","first-page":"2702","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin D","year":"2003","unstructured":"Marin D, Goldman JM, Olavarria E, Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102:2702\u20132703; author reply 2703\u20132704."},{"key":"B150","series-title":"Blood","first-page":"2154","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour E","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154\u20132160."},{"key":"B151","series-title":"Cancer","first-page":"551","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian HM","year":"2009","unstructured":"Kantarjian HM, Larson RA, Guilhot F, Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551\u2013560."},{"key":"B152","series-title":"Blood","first-page":"915","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung DT","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015;125:915\u2013923."},{"key":"B153","series-title":"Lancet Haematol","first-page":"e581","article-title":"Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial","volume":"3","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, De Souza CA, Ayala M, Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol 2016;3:e581\u2013591."},{"key":"B154","series-title":"Leukemia","first-page":"2064","article-title":"Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study","volume":"34","author":"Cortes JE","year":"2020","unstructured":"Cortes JE, Jiang Q, Wang J, Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia 2020;34:2064\u20132073."},{"key":"B155","series-title":"Am J Hematol","first-page":"869","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah NP","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016;91:869\u2013874."},{"key":"B156","series-title":"Leukemia","first-page":"107","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles FJ","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107\u2013112."},{"key":"B157","series-title":"Haematologica","first-page":"1298","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini C","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica 2018;103:1298\u20131307."},{"key":"B158","series-title":"Am J Hematol","first-page":"1206","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol 2016;91:1206\u20131214."},{"key":"B159","series-title":"Leukemia","first-page":"2125","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia 2020;34:2125\u20132137."},{"key":"B160","series-title":"Blood","first-page":"393","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018;132:393\u2013404."},{"key":"B161","series-title":"Blood","first-page":"2042","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes JE","year":"2021","unstructured":"Cortes JE, Apperley J, Lomaia E, Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 2021;138:2042\u20132050."},{"key":"B162","series-title":"N Engl J Med","first-page":"2315","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381:2315\u20132326."},{"key":"B163","series-title":"Blood","first-page":"2031","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a D","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031\u20132041."},{"key":"B164","series-title":"Leukemia","first-page":"617","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus A","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 2023;37:617\u2013626."},{"key":"B165","series-title":"Leuk Res","first-page":"84","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer DJ","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res 2016;48:84\u201391."},{"key":"B166","series-title":"Blood Adv","first-page":"851","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain P","year":"2019","unstructured":"Jain P, Kantarjian HM, Boddu PC, Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 2019;3:851\u2013861."},{"key":"B167","series-title":"Hematol Oncol","first-page":"296","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci G","year":"2019","unstructured":"Caocci G, Mulas O, Abruzzese E, Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol 2019;37:296\u2013302."},{"key":"B168","series-title":"Heart Fail Rev","first-page":"447","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia G","year":"2020","unstructured":"Casavecchia G, Galderisi M, Novo G, Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev 2020;25:447\u2013456."},{"key":"B169","series-title":"Blood","first-page":"2573","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes JE","year":"2012","unstructured":"Cortes JE, Lipton JH, Rea D, Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120:2573\u20132580."},{"key":"B170","series-title":"Am J Hematol","first-page":"350","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes JE","year":"2013","unstructured":"Cortes JE, Digumarti R, Parikh PM, Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 2013;88:350\u2013354."},{"key":"B171","series-title":"Blood","first-page":"4361","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg RJ","year":"2009","unstructured":"Garg RJ, Kantarjian HM, O\u2019Brien S, The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361\u20134368."},{"key":"B172","series-title":"Lancet Oncol","first-page":"e315","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen RW","year":"2014","unstructured":"van Leeuwen RW, van Gelder T, Mathijssen RH, Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15:e315\u2013326."},{"key":"B173","series-title":"Ann Hematol","first-page":"2089","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?","volume":"97","author":"Osorio S","year":"2018","unstructured":"Osorio S, Escudero-Vilaplana V, G\u00f3mez-Centuri\u00f3n I, Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? Ann Hematol 2018;97:2089\u20132098."},{"key":"B174","series-title":"Blood","first-page":"5401","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens L","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401\u20135411."},{"key":"B175","series-title":"J Clin Oncol","first-page":"2381","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin D","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381\u20132388."},{"key":"B176","series-title":"Blood","first-page":"3733","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim AR","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011;117:3733\u20133736."},{"key":"B177","series-title":"Curr Med Res Opin","first-page":"2861","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu EQ","year":"2010","unstructured":"Wu EQ, Guerin A, Yu AP, Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861\u20132869."},{"key":"B178","series-title":"Curr Med Res Opin","first-page":"213","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood MU","year":"2012","unstructured":"Yood MU, Oliveria SA, Cziraky M, Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012;28:213\u2013219."},{"key":"B179","series-title":"Clin Lymphoma Myeloma","first-page":"S82","article-title":"Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"8","author":"Quint\u00e1s-Cardama A","year":"2008","unstructured":"Quint\u00e1s-Cardama A, Cortes JE, Kantarjian HM. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 2008;8(Suppl 3):S82\u201388."},{"key":"B180","series-title":"J Support Oncol","first-page":"14","article-title":"Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner","volume":"10","author":"Cornelison M","year":"2012","unstructured":"Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 2012;10:14\u201324."},{"key":"B181","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"286","article-title":"Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study","volume":"16","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Lipton JH, Miller CB, Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk 2016;16:286\u2013296."},{"key":"B182","series-title":"Ann Hematol","first-page":"1357","article-title":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study","volume":"97","author":"Kim DW","year":"2018","unstructured":"Kim DW, Saussele S, Williams LA, Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol 2018;97:1357\u20131367."},{"key":"B183","series-title":"Blood","first-page":"3739","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas J","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739\u20133745."},{"key":"B184","series-title":"Cancer Res","first-page":"9809","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon FX","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809\u20139816."},{"key":"B185","series-title":"Br J Pharmacol","first-page":"1153","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus C","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Ap\u00e1ti A, Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009;158:1153\u20131164."},{"key":"B186","series-title":"Blood","first-page":"3496","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard S","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496\u20133499."},{"key":"B187","series-title":"Blood","first-page":"4022","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson RA","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022\u20134028."},{"key":"B188","series-title":"Fundam Clin Pharmacol","first-page":"690","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet S","year":"2013","unstructured":"Bouchet S, Titier K, Moore N, Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol 2013;27:690\u2013697."},{"key":"B189","series-title":"Haematologica","first-page":"907","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White DL","year":"2012","unstructured":"White DL, Radich J, Soverini S, Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica 2012;97:907\u2013914."},{"key":"B190","series-title":"Blood","first-page":"3348","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis A","year":"2008","unstructured":"Giannoudis A, Davies A, Lucas CM, Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348\u20133354."},{"key":"B191","series-title":"Clin Cancer Res","first-page":"3881","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase DK","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881\u20133888."},{"key":"B192","series-title":"Leukemia","first-page":"1999","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies A","year":"2009","unstructured":"Davies A, Jordanides NE, Giannoudis A, Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23:1999\u20132006."},{"key":"B193","series-title":"Blood","first-page":"697","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White DL","year":"2006","unstructured":"White DL, Saunders VA, Dang P, OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697\u2013704."},{"key":"B194","series-title":"Blood","first-page":"276","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford S","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276\u2013283."},{"key":"B195","series-title":"J Clin Oncol","first-page":"4100","article-title":"ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"23","author":"Soverini S","year":"2005","unstructured":"Soverini S, Martinelli G, Rosti G, ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100\u20134109."},{"key":"B196","series-title":"Leukemia","first-page":"1061","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini FE","year":"2006","unstructured":"Nicolini FE, Corm S, L\u00ea QH, Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;20:1061\u20131066."},{"key":"B197","series-title":"Clin Cancer Res","first-page":"7374","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini S","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374\u20137379."},{"key":"B198","series-title":"J Clin Oncol","first-page":"4806","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad JS","year":"2008","unstructured":"Khorashad JS, de Lavallade H, Apperley JF, Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806\u20134813."},{"key":"B199","series-title":"Blood","first-page":"2168","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant BCR-ABL kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini S","year":"2009","unstructured":"Soverini S, Gnani A, Colarossi S, Philadelphia-positive patients who already harbor imatinib-resistant BCR-ABL kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168\u20132171."},{"key":"B200","series-title":"J Clin Oncol","first-page":"4204","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes T","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204\u20134210."},{"key":"B201","series-title":"Int J Hematol","first-page":"689","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with E255K\/V BCR-ABL kinase domain mutations","volume":"107","author":"Naqvi K","year":"2018","unstructured":"Naqvi K, Cortes JE, Luthra R, Characteristics and outcome of chronic myeloid leukemia patients with E255K\/V BCR-ABL kinase domain mutations. Int J Hematol 2018;107:689\u2013695."},{"key":"B202","series-title":"Haematologica","first-page":"1238","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini FE","year":"2007","unstructured":"Nicolini FE, Hayette S, Corm S, Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007;92:1238\u20131241."},{"key":"B203","series-title":"Blood","first-page":"53","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour E","year":"2008","unstructured":"Jabbour E, Kantarjian HM, Jones D, Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53\u201355."},{"key":"B204","series-title":"Haematologica","first-page":"401","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini S","year":"2007","unstructured":"Soverini S, Colarossi S, Gnani A, Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401\u2013404."},{"key":"B205","series-title":"Blood","first-page":"4839","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour E","year":"2008","unstructured":"Jabbour E, Kantarjian HM, Jones D, Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008;112:4839\u20134842."},{"key":"B206","series-title":"Blood","first-page":"4944","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller MC","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim DW, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944\u20134953."},{"key":"B207","series-title":"Blood","first-page":"3403","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury HJ","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood 2012;119:3403\u20133412."},{"key":"B208","series-title":"Cancer Cell","first-page":"431","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide CA","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 2019;36:431\u2013443.e5."},{"key":"B209","series-title":"Blood","first-page":"489","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad JS","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013;121:489\u2013498."},{"key":"B210","series-title":"Cancer Cell","first-page":"428","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie MS","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014;26:428\u2013442."},{"key":"B211","series-title":"Blood","first-page":"703","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger MW","year":"2016","unstructured":"Deininger MW, Hodgson JG, Shah NP, Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 2016;127:703\u2013712."},{"key":"B212","series-title":"J Mol Diagn","first-page":"177","article-title":"An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy","volume":"10","author":"Laudadio J","year":"2008","unstructured":"Laudadio J, Deininger MW, Mauro MJ, An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn 2008;10:177\u2013180."},{"key":"B213","series-title":"Leuk Res","first-page":"108","article-title":"Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS)","volume":"49","author":"Berman E","year":"2016","unstructured":"Berman E, Jhanwar S, Hedvat C, Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS). Leuk Res 2016;49:108\u2013112."},{"key":"B214","series-title":"Leuk Res","first-page":"10","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini S","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014;38:10\u201320."},{"key":"B215","series-title":"Blood","first-page":"2926","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford S","year":"2004","unstructured":"Branford S, Rudzki Z, Parkinson I, Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926\u20132932."},{"key":"B216","series-title":"Haematologica","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang L","year":"2006","unstructured":"Wang L, Knight K, Lucas C, The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235\u2013239."},{"key":"B217","series-title":"J Clin Oncol","first-page":"3659","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian HM","year":"2009","unstructured":"Kantarjian HM, Shan J, Jones D, Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009;27:3659\u20133663."},{"key":"B218","series-title":"Br J Haematol","first-page":"373","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin D","year":"2009","unstructured":"Marin D, Khorashad JS, Foroni L, Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009;145:373\u2013375."},{"key":"B219","series-title":"Blood","first-page":"2598","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press RD","year":"2009","unstructured":"Press RD, Willis SG, Laudadio J, Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598\u20132605."},{"key":"B220","series-title":"Lancet Oncol","first-page":"1029","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon FX","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029\u20131035."},{"key":"B221","series-title":"J Clin Oncol","first-page":"298","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne G","year":"2017","unstructured":"Etienne G, Guilhot J, R\u00e9a D, Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 2017;35:298\u2013305."},{"key":"B222","series-title":"Eur J Cancer","first-page":"3242","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen N","year":"2013","unstructured":"Thielen N, van der Holt B, Cornelissen JJ, Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 2013;49:3242\u20133246."},{"key":"B223","series-title":"J Clin Oncol","first-page":"424","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot P","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424\u2013430."},{"key":"B224","series-title":"Am J Hematol","first-page":"910","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori S","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P, Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 2015;90:910\u2013914."},{"key":"B225","series-title":"Haematologica","first-page":"717","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee SE","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 2016;101:717\u2013723."},{"key":"B226","series-title":"Leukemia","first-page":"2572","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross DM","year":"2018","unstructured":"Ross DM, Pagani IS, Shanmuganathan N, Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia 2018;32:2572\u20132579."},{"key":"B227","series-title":"Blood","first-page":"846","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"R\u00e9a D","year":"2017","unstructured":"R\u00e9a D, Nicolini FE, Tulliez M, Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 2017;129:846\u2013854."},{"key":"B228","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"353","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada M","year":"2018","unstructured":"Okada M, Imagawa J, Tanaka H, Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk 2018;18:353\u2013360.e1."},{"key":"B229","series-title":"Lancet Oncol","first-page":"747","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele S","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018;19:747\u2013757."},{"key":"B230","series-title":"Leuk Lymphoma","first-page":"650","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah NP","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma 2020;61:650\u2013659."},{"key":"B231","series-title":"Lancet Haematol","first-page":"e218","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura S","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2020;7:e218\u2013225."},{"key":"B232","series-title":"Leukemia","first-page":"1344","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich JP","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T, Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia 2021;35:1344\u20131355."},{"key":"B233","series-title":"Leukemia","first-page":"1631","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes TP","year":"2021","unstructured":"Hughes TP, Clementino NCD, Fominykh M, Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia 2021;35:1631\u20131642."},{"key":"B234","series-title":"Haematologica","first-page":"2356","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study","volume":"107","author":"Gugliotta G","year":"2022","unstructured":"Gugliotta G, Castagnetti F, Breccia M, Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. Haematologica 2022;107:2356\u20132364."},{"key":"B235","series-title":"Cancer","first-page":"4403","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros L","year":"2017","unstructured":"Legros L, Nicolini FE, Etienne G, Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer 2017;123:4403\u20134410."},{"key":"B236","series-title":"Leukemia","first-page":"2416","article-title":"Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI","volume":"35","author":"Richter J","year":"2021","unstructured":"Richter J, L\u00fcbking A, S\u00f6derlund S, Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia 2021;35:2416\u20132418."},{"key":"B237","series-title":"Blood","first-page":"1196","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan N","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood 2021;137:1196\u20131207."},{"key":"B238","series-title":"J Hematol Oncol","first-page":"143","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ, Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 2018;11:143."},{"key":"B239","series-title":"Leuk Res","first-page":"106690","article-title":"Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2012positive leukemias","volume":"111","author":"Kota V","year":"2021","unstructured":"Kota V, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2012positive leukemias. Leuk Res 2021;111:106690."},{"key":"B240","series-title":"Cancer","first-page":"67","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi K","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J, Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2020;126:67\u201375."},{"key":"B241","series-title":"Am J Hematol","first-page":"1413","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG, Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol 2022;97:1413\u20131418."},{"key":"B242","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"370","article-title":"Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg","volume":"17","author":"Itamura H","year":"2017","unstructured":"Itamura H, Kubota Y, Shindo T, Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk 2017;17:370\u2013374."},{"key":"B243","series-title":"Lancet Haematol","first-page":"e902","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai K","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T, Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2021;8:e902\u2013911."},{"key":"B244","series-title":"Am J Hematol","first-page":"960","article-title":"Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients","volume":"85","author":"Visani G","year":"2010","unstructured":"Visani G, Breccia M, Gozzini A, Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. Am J Hematol 2010;85:960\u2013963."},{"key":"B245","series-title":"Ann Hematol","first-page":"1345","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib","volume":"92","author":"La Ros\u00e9e P","year":"2013","unstructured":"La Ros\u00e9e P, Martiat P, Leitner A, Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013;92:1345\u20131350."},{"key":"B246","series-title":"Eur J Haematol","first-page":"243","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen H","year":"2015","unstructured":"Hjorth-Hansen H, Stenke L, S\u00f6derlund S, Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2015;94:243\u2013250."},{"key":"B247","series-title":"Intern Med","first-page":"17","article-title":"The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the KANTO CML study group","volume":"57","author":"Iriyama N","year":"2018","unstructured":"Iriyama N, Ohashi K, Hashino S, The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the KANTO CML study group. Intern Med 2018;57:17\u201323."},{"key":"B248","series-title":"Cancer Sci","first-page":"1071","article-title":"Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study","volume":"103","author":"Ohnishi K","year":"2012","unstructured":"Ohnishi K, Nakaseko C, Takeuchi J, Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 2012;103:1071\u20131078."},{"key":"B249","series-title":"Med Oncol","first-page":"38","article-title":"Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase","volume":"35","author":"Tokuhira M","year":"2018","unstructured":"Tokuhira M, Kimura Y, Sugimoto K, Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol 2018;35:38."},{"key":"B250","series-title":"Leuk Res","first-page":"109","article-title":"Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study","volume":"67","author":"Hiwase D","year":"2018","unstructured":"Hiwase D, Tan P, D\u2019Rozario J, Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leuk Res 2018;67:109\u2013115."},{"key":"B251","series-title":"Am J Hematol","first-page":"E260","article-title":"Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs","volume":"95","author":"Iurlo A","year":"2020","unstructured":"Iurlo A, Cattaneo D, Malato A, Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. Am J Hematol 2020;95:E260\u2013263."},{"key":"B252","series-title":"Blood Cancer J","first-page":"e347","article-title":"Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment","volume":"5","author":"Russo D","year":"2015","unstructured":"Russo D, Malagola M, Skert C, Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J 2015;5:e347."},{"key":"B253","series-title":"Leuk Lymphoma","first-page":"370","article-title":"A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment","volume":"57","author":"Faber E","year":"2016","unstructured":"Faber E, Divok\u00e1 M, Skoumalov\u00e1 I, A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma 2016;57:370\u2013375."},{"key":"B254","series-title":"Ann Hematol","first-page":"81","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes F","year":"2017","unstructured":"Cervantes F, Correa JG, P\u00e9rez I, Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol 2017;96:81\u201385."},{"key":"B255","series-title":"Lancet Haematol","first-page":"e310","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark RE","year":"2017","unstructured":"Clark RE, Polydoros F, Apperley JF, De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol 2017;4:e310\u2013316."},{"key":"B256","series-title":"Lancet Haematol","first-page":"e375","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark RE","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol 2019;6:e375\u2013383."},{"key":"B257","series-title":"Cancer","first-page":"3438","article-title":"Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: results of a retrospective study","volume":"126","author":"Cayssials E","year":"2020","unstructured":"Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: results of a retrospective study. Cancer 2020;126:3438\u20133447."},{"key":"B258","series-title":"Br J Haematol","first-page":"346","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani S","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R, TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol 2021;193:346\u2013355."},{"key":"B259","series-title":"Cancer Med","first-page":"1726","article-title":"Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: first interim analysis of OPTkIMA study","volume":"10","author":"Malagola M","year":"2021","unstructured":"Malagola M, Iurlo A, Abruzzese E, Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: first interim analysis of OPTkIMA study. Cancer Med 2021;10:1726\u20131737."},{"key":"B260","series-title":"Leukemia","first-page":"1336","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann VS","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 2015;29:1336\u20131343."},{"key":"B261","series-title":"Br J Haematol","first-page":"374","article-title":"Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy","volume":"137","author":"Ramasamy K","year":"2007","unstructured":"Ramasamy K, Hayden J, Lim Z, Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007;137:374\u2013375."},{"key":"B262","series-title":"Leuk Res","first-page":"519","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases","volume":"32","author":"Breccia M","year":"2008","unstructured":"Breccia M, Cannella L, Montefusco E, Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008;32:519\u2013520."},{"key":"B263","series-title":"Arch Gynecol Obstet","first-page":"133","article-title":"Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib","volume":"283","author":"Oweini H","year":"2011","unstructured":"Oweini H, Otrock ZK, Mahfouz RA, Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 2011;283:133\u2013134."},{"key":"B264","series-title":"J Oncol Pharm Pract","first-page":"243","article-title":"Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: a preliminary report","volume":"20","author":"Ghalaut VS","year":"2014","unstructured":"Ghalaut VS, Prakash G, Bansal P, Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: a preliminary report. J Oncol Pharm Pract 2014;20:243\u2013248."},{"key":"B265","series-title":"Leuk Res","first-page":"47","article-title":"Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre","volume":"39","author":"Alizadeh H","year":"2015","unstructured":"Alizadeh H, Jaafar H, Rajnics P, Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res 2015;39:47\u201351."},{"key":"B266","series-title":"Blood","first-page":"5505","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye SM","year":"2008","unstructured":"Pye SM, Cortes JE, Ault P, The effects of imatinib on pregnancy outcome. Blood 2008;111:5505\u20135508."},{"key":"B267","series-title":"Am J Hematol","first-page":"1111","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes JE","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E, The impact of dasatinib on pregnancy outcomes. Am J Hematol 2015;90:1111\u20131115."},{"key":"B268","series-title":"J Oncol Pharm Pract","first-page":"121","article-title":"Experience with dasatinib and nilotinib use in pregnancy","volume":"24","author":"Barkoulas T","year":"2018","unstructured":"Barkoulas T, Hall PD. Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract 2018;24:121\u2013128."},{"key":"B269","series-title":"Sci Rep","first-page":"2535","article-title":"Imatinib treatments have long-term impact on placentation and embryo survival","volume":"9","author":"Salem W","year":"2019","unstructured":"Salem W, Li K, Krapp C, Imatinib treatments have long-term impact on placentation and embryo survival. Sci Rep 2019;9:2535."},{"key":"B270","series-title":"J Glob Oncol","first-page":"1","article-title":"Pregnancy outcomes in chronic myeloid leukemia: a single center experience","volume":"5","author":"Madabhavi I","year":"2019","unstructured":"Madabhavi I, Sarkar M, Modi M, Pregnancy outcomes in chronic myeloid leukemia: a single center experience. J Glob Oncol 2019;5:1\u201311."},{"key":"B271","series-title":"Int J Hematol Oncol","first-page":"IJH26","article-title":"Pregnancy outcomes in patients treated with bosutinib","volume":"9","author":"Cortes JE","year":"2020","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol 2020;9:IJH26."},{"key":"B272","series-title":"Leuk Lymphoma","first-page":"909","article-title":"Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience","volume":"62","author":"Assi R","year":"2021","unstructured":"Assi R, Kantarjian HM, Keating M, Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience. Leuk Lymphoma 2021;62:909\u2013917."},{"key":"B273","series-title":"J Clin Oncol","first-page":"1204","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault P","year":"2006","unstructured":"Ault P, Kantarjian HM, O\u2019Brien S, Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204\u20131208."},{"key":"B274","series-title":"Blood","first-page":"1014","article-title":"Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response","volume":"116","author":"Kuwabara A","year":"2010","unstructured":"Kuwabara A, Babb A, Ibrahim A, Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2010;116:1014\u20131016."},{"key":"B275","series-title":"Curr Hematol Malig Rep","first-page":"33","article-title":"Family planning and pregnancy in patients with chronic myeloid leukemia","volume":"18","author":"Berman E","year":"2023","unstructured":"Berman E. Family planning and pregnancy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep 2023;18:33\u201339."},{"key":"B276","series-title":"Leuk Lymphoma","first-page":"1796","article-title":"The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia","volume":"60","author":"Lasica M","year":"2019","unstructured":"Lasica M, Willcox A, Burbury K, The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma 2019;60:1796\u20131802."},{"key":"B277","series-title":"In Vivo","first-page":"1593","article-title":"Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib","volume":"33","author":"Stella S","year":"2019","unstructured":"Stella S, Tirr\u00f3 E, Massimino M, Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib. In Vivo 2019;33:1593\u20131598."},{"key":"B278","series-title":"Jpn J Clin Oncol","first-page":"215","article-title":"Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature","volume":"34","author":"Ali R","year":"2004","unstructured":"Ali R, Ozkalemka\u015f F, Ozkocaman V, Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol 2004;34:215\u2013217."},{"key":"B279","series-title":"Int J Hematol","first-page":"459","article-title":"Pregnancies in patients with chronic myeloid leukemia in the era of imatinib","volume":"84","author":"Koh LP","year":"2006","unstructured":"Koh LP, Kanagalingam D. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. Int J Hematol 2006;84:459\u2013462."},{"key":"B280","series-title":"Ann Hematol","first-page":"S167","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani R","year":"2015","unstructured":"Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015;94(Suppl 2):S167\u2013176."},{"key":"B281","series-title":"Transfusion","first-page":"456","article-title":"Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature","volume":"58","author":"Staley EM","year":"2018","unstructured":"Staley EM, Simmons SC, Feldman AZ, Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature. Transfusion 2018;58:456\u2013460."},{"key":"B282","series-title":"Obstet Gynecol Surv","first-page":"49","article-title":"Aspirin and reproductive outcomes","volume":"63","author":"James AH","year":"2008","unstructured":"James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008;63:49\u201357."},{"key":"B283","series-title":"Curr Opin Obstet Gynecol","first-page":"573","article-title":"The use of low-molecular-weight heparins in pregnancy--how safe are they?","volume":"19","author":"Deruelle P","year":"2007","unstructured":"Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy--how safe are they? Curr Opin Obstet Gynecol 2007;19:573\u2013577."},{"key":"B284","series-title":"Eur J Gynaecol Oncol","first-page":"89","article-title":"Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report","volume":"21","author":"Baykal C","year":"2000","unstructured":"Baykal C, Zengin N, Co\u015fkun F, Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report. Eur J Gynaecol Oncol 2000;21:89\u201390."},{"key":"B285","series-title":"Leukemia","first-page":"1309","article-title":"Exposure to hydroxyurea during pregnancy: a case series","volume":"15","author":"Thauvin-Robinet C","year":"2001","unstructured":"Thauvin-Robinet C, Maingueneau C, Robert E, Exposure to hydroxyurea during pregnancy: a case series. Leukemia 2001;15:1309\u20131311."},{"key":"B286","series-title":"Leukemia","first-page":"1202","article-title":"Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea","volume":"16","author":"Fadilah SA","year":"2002","unstructured":"Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 2002;16:1202\u20131203."},{"key":"B287","series-title":"Eur J Haematol","first-page":"774","article-title":"Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era","volume":"101","author":"Balsat M","year":"2018","unstructured":"Balsat M, Etienne M, Elhamri M, Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era. Eur J Haematol 2018;101:774\u2013780."},{"key":"B288","series-title":"Haematologica","first-page":"e182","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series","volume":"101","author":"Beauverd Y","year":"2016","unstructured":"Beauverd Y, Radia D, Cargo C, Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 2016;101:e182\u2013184."},{"key":"B289","series-title":"J Cancer Res Clin Oncol","first-page":"1481","article-title":"Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety","volume":"147","author":"Schrickel L","year":"2021","unstructured":"Schrickel L, Heidel FH, Sadjadian P, Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin Oncol 2021;147:1481\u20131491."},{"key":"B290","series-title":"J Clin Oncol","first-page":"1429","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert A","year":"2010","unstructured":"Burchert A, M\u00fcller MC, Kostrewa P, Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429\u20131435."},{"key":"B291","series-title":"Blood","article-title":"Pregnancy management in cml patients: to treat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) database","volume":"134","author":"Abruzzese E","year":"2019","unstructured":"Abruzzese E, Turkina AG, Apperley JF, Pregnancy management in cml patients: to treat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) database. Blood 2019;134(Suppl 1):Abstract 632."},{"key":"B292","series-title":"J Perinatol","first-page":"241","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell MA","year":"2007","unstructured":"Russell MA, Carpenter MW, Akhtar M, Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007;27:241\u2013243."},{"key":"B293","series-title":"Arch Gynecol Obstet","first-page":"169","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali R","year":"2009","unstructured":"Ali R, Ozkalemkas F, Kimya Y, Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009;280:169\u2013175."},{"key":"B294","article-title":"Drugs and lactation database (LactMed)","unstructured":"US National Institutes of Health. Drugs and lactation database (LactMed). Accessed November 1, 2023. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501922\/"},{"key":"B295","series-title":"Mediterr J Hematol Infect Dis","first-page":"e2018027","article-title":"Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review","volume":"10","author":"Chelysheva E","year":"2018","unstructured":"Chelysheva E, Aleshin S, Polushkina E, Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review. Mediterr J Hematol Infect Dis 2018;10:e2018027."},{"key":"B296","series-title":"Mediterr J Hematol Infect Dis","first-page":"e2014028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese E","year":"2014","unstructured":"Abruzzese E, Trawinska MM, Perrotti AP, Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 2014;6:e2014028."},{"key":"B297","series-title":"Leukemia","first-page":"1044","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044\u20131054."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/1\/article-p43.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/1\/article-p43.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/1\/article-p43.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:30:09Z","timestamp":1708702209000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/1\/article-p43.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":297,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0007","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}